indee Partners with ide Group to Develop Cutting-Edge Cell Therapy Technology
Malvern, PA, August 19, 2016 --(PR.com)-- ide Group is pleased to announce that it is partnering with indee to help realise a user-friendly piece of hardware for the development of simple and scalable cell therapy technologies.
indee is a company founded by Ryan Pawell and Matthew Burkhardt that aims to accelerate gene therapy technology. During his PhD at University of NSW, Pawell invented a patent-pending microfluidic chip. The chip serves as a platform technology that could help reverse the effects of illnesses such as cancer, HIV and neurodegenerative disorders.
Cell therapy gained international attention last year when a one-year-old’s cancer was reversed using “designer cells” created using viruses. Yet, the cost of these designer cells means that cell therapy treatment still remains out of reach for the majority of the population. indee hopes that by replacing viruses with a microfluidic chip, the manufacturing costs will be reduced.
“A big problem with these cell therapies is that they are expensive, difficult to manufacture and existing manufacturing processes are unreliable. You can’t really market these therapies if they cost $50,000 to make and a large portion of them fail,” Pawell described.
Pawell and Burkhardt recently demonstrated the technology is clinically relevant, which may lead to significantly lower therapeutic manufacturing costs while maintaining quality and increasing manufacturing scale.
The proposed hardware project in collaboration with ide Group will help simplify the delivery workflow, streamline the process for testing the technology in a laboratory setting and pave the way for future commercialisation of a medical device.
ide Group Managing Director, George Sidis said, “we are very excited to be collaborating with indee on this project to realise a technology that once it becomes a commercial reality, has the potential to change a significant number of lives for the better.”
About indee
indee is an Australian-American biotechnology startup backed by IndieBio and SOSV. indee aims to accelerate gene therapy.
Visit the indee website.
About ide Group
Better futures start here.
When someone gives us their hope, we own that hope. And the uncertainty that comes along with it. What we care most about is changing lives, growing businesses and realising value.
Uncertainty is the scariest part of any new project. There are always more things you don’t know than things you do. We don’t have all the answers, but we've been here before and know the right questions to ask. When it gets tough, when something goes wrong, we will be standing there with you. Doing the hard yards to get the job done.
And through it all, we never lose sight of the real goal; creating products that change lives, grow new organisations and build better futures.
indee is a company founded by Ryan Pawell and Matthew Burkhardt that aims to accelerate gene therapy technology. During his PhD at University of NSW, Pawell invented a patent-pending microfluidic chip. The chip serves as a platform technology that could help reverse the effects of illnesses such as cancer, HIV and neurodegenerative disorders.
Cell therapy gained international attention last year when a one-year-old’s cancer was reversed using “designer cells” created using viruses. Yet, the cost of these designer cells means that cell therapy treatment still remains out of reach for the majority of the population. indee hopes that by replacing viruses with a microfluidic chip, the manufacturing costs will be reduced.
“A big problem with these cell therapies is that they are expensive, difficult to manufacture and existing manufacturing processes are unreliable. You can’t really market these therapies if they cost $50,000 to make and a large portion of them fail,” Pawell described.
Pawell and Burkhardt recently demonstrated the technology is clinically relevant, which may lead to significantly lower therapeutic manufacturing costs while maintaining quality and increasing manufacturing scale.
The proposed hardware project in collaboration with ide Group will help simplify the delivery workflow, streamline the process for testing the technology in a laboratory setting and pave the way for future commercialisation of a medical device.
ide Group Managing Director, George Sidis said, “we are very excited to be collaborating with indee on this project to realise a technology that once it becomes a commercial reality, has the potential to change a significant number of lives for the better.”
About indee
indee is an Australian-American biotechnology startup backed by IndieBio and SOSV. indee aims to accelerate gene therapy.
Visit the indee website.
About ide Group
Better futures start here.
When someone gives us their hope, we own that hope. And the uncertainty that comes along with it. What we care most about is changing lives, growing businesses and realising value.
Uncertainty is the scariest part of any new project. There are always more things you don’t know than things you do. We don’t have all the answers, but we've been here before and know the right questions to ask. When it gets tough, when something goes wrong, we will be standing there with you. Doing the hard yards to get the job done.
And through it all, we never lose sight of the real goal; creating products that change lives, grow new organisations and build better futures.
Contact
ide Group
Erin Evanochko
61 02 9647 2660
www.idegroup.com.au
Erin Evanochko
61 02 9647 2660
www.idegroup.com.au
Contact
Categories